Save Product
Product Details
Materials Provided
IDComponentsSizeEP141-C01High-bind Plate1 plateEP141-C02Human VEGF R250 μgEP141-C03Biotinylated Human VEGFA10 μgEP141-C04Anti-VEGF Neutralizing Antibody20 μgEP141-C05Streptavidin-HRP10 μgEP141-C06Coating Buffer12 mLEP141-C0710xWashing Buffer50 mLEP141-C08Blocking Buffer50 mLEP141-C09Substrate Solution24 mLEP141-C10Stop Solution7 mLProduct Overview
VEGFA [Biotinylated] : VEGFR2 Inhibitor Screening ELISA Kit is based on a competition-ELISA method, is used to screening for inhibitors of human VEGFA binding to human VEGFR2. The kit is designed to provide a reliable solution for the screening of antibodies and small molecule inhibitors in the early stages, as well as QC release, to help researchers quickly screen and validate drugs, effectively improving research and development efficiency. It can also be used as a universal detection tool to identify the ability of human VEGFA binding to human VEGFR2.
Reconstitution
Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
Storage
1. Unopened kit should be stored at 2℃-8℃ upon receiving.
2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.
3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Typical Data
Please refer to DS document for the assay protocol.
INHIBITION OF VEGFA[Biotinylated]: VEGF R2 BINDING BY ANTI-VEGFA NEUTRALIZING ANTIBODY
Serial dilutions of Anti-VEGFA Neutralizing antibody (Catalog # EP141-C04) (1:1 serial dilution, from 20 μg/mL to 0.01μg/mL) was added into Biotinylated VEGFA: VEGF R2 binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).
Customer Reviews Writing Reviews
Recent Advances
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
